Assessment of a potential tumor-seeking manganese metalloporphyrin contrast agent in a mouse model

• Published in: Magnetic resonance in medicine Vol. 47; no. 3; pp. 549 - 553
• Main Authors: Takehara, Yasuo, Sakahara, Harumi, Masunaga, Hatsuko, Isogai, Satoshi, Kodaira, Nami, Sugiyama, Masahiro, Takeda, Hiroyasu, Saga, Tsuneo, Nakajima, Susumu, Sakata, Isao
• Format: Journal Article
• Language: English
• Published: New York Wiley Subscription Services, Inc., A Wiley Company 01.03.2002; Williams & Wilkins
• Subjects: Analysis of Variance; Animals; Biological and medical sciences; Carcinoma, Squamous Cell - pathology; contrast media; Contrast Media - administration & dosage; Contrast Media - pharmacokinetics; Contrast media. Radiopharmaceuticals; Gadolinium DTPA - administration & dosage; Gadolinium DTPA - pharmacokinetics; Investigative techniques, diagnostic techniques (general aspects); magnetic resonance imaging; Magnetic Resonance Imaging - methods; Manganese - administration & dosage; Manganese - pharmacokinetics; Medical sciences; metalloporphyrins; Metalloporphyrins - administration & dosage; Metalloporphyrins - pharmacokinetics; Mice; Mice, Inbred C3H; Miscellaneous. Technology; neoplasms; Neoplasms, Experimental; Pharmacology. Drug treatments; Radiodiagnosis. Nmr imagery. Nmr spectrometry; Skin Neoplasms - pathology; Statistics, Nonparametric; Tissue Distribution; Animal model; Rodentia; Paramagnetic contrast agent; Bioavailability; Experimental study; Metabolism; Nuclear magnetic resonance imaging; Vertebrata; Sensitivity; Mammalia; Mouse; Animal; Tumor; Metalloporphyrin; Pharmacokinetics; Manganese
• ISSN: 0740-3194; 1522-2594
• DOI: 10.1002/mrm.10109

The performance of a newly developed potential tumor‐seeking magnetic resonance (MR) contrast agent α‐Aqua‐13,17‐bis(1‐carboxypropionyl) carbamoylethyl‐3,8‐bis(1‐phenethyloxyethyl)‐β‐hydroxy‐2,7,12,18‐tetramethyl‐porphyrinato manganese (III) (HOP‐8P) was tested using a mouse model. Tumor‐bearing (SCC‐VII) mice were imaged using a 1.5T MR imager before and after intravenous administration of 0.1 mmol/kg of HOP‐8P. A biodistribution analysis was performed using an optical emission spectrometer. Significant enhancement of the transplanted tumor was observed in MR images 24 h after intravenous injection of HOP‐8P. The biodistribution assessment of manganese also correlated with the results of the imaging study. During the 24‐h period following contrast administration, HOP‐8P was consistently cleared from the circulation, liver, kidneys, and muscle; however, it was progressively accumulated within the tumor. HOP‐8P is a promising tumor‐seeking metalloporphyrin MR contrast agent with a wide imaging window. Magn Reson Med 47:549–553, 2002. © 2002 Wiley‐Liss, Inc.